Erik Gerdtsson, Milind Pore, Jana-Aletta Thiele, Anna Sandström Gerdtsson, Paymaneh D Malihi, Rafael Nevarez, Anand Kolatkar, Carmen Ruiz Velasco, Sophia Wix, Mohan Singh, Anders Carlsson, Amado J Zurita, Christopher Logothetis, Akil A Merchant, James Hicks, Peter Kuhn
{"title":"Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry.","authors":"Erik Gerdtsson, Milind Pore, Jana-Aletta Thiele, Anna Sandström Gerdtsson, Paymaneh D Malihi, Rafael Nevarez, Anand Kolatkar, Carmen Ruiz Velasco, Sophia Wix, Mohan Singh, Anders Carlsson, Amado J Zurita, Christopher Logothetis, Akil A Merchant, James Hicks, Peter Kuhn","doi":"10.1088/2057-1739/aaa013","DOIUrl":null,"url":null,"abstract":"<p><p>Molecular analysis of circulating and disseminated tumor cells (CTCs/DTCs) has great potential as a means for continuous evaluation of prognosis and treatment efficacy in near-real time through minimally invasive liquid biopsies. To realize this potential, however, methods for molecular analysis of these rare cells must be developed and validated. Here, we describe the integration of imaging mass cytometry (IMC) using metal-labeled antibodies as implemented on the Fluidigm Hyperion Imaging System into the workflow of the previously established High Definition Single Cell Analysis (HD-SCA) assay for liquid biopsies, along with methods for image analysis and signal normalization. Using liquid biopsies from a metastatic prostate cancer case, we demonstrate that IMC can extend the reach of CTC characterization to include dozens of protein biomarkers, with the potential to understand a range of biological properties that could affect therapeutic response, metastasis and immune surveillance when coupled with simultaneous phenotyping of thousands of leukocytes.</p>","PeriodicalId":91466,"journal":{"name":"Convergent science physical oncology","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430142/pdf/nihms-936703.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Convergent science physical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1088/2057-1739/aaa013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/16 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Molecular analysis of circulating and disseminated tumor cells (CTCs/DTCs) has great potential as a means for continuous evaluation of prognosis and treatment efficacy in near-real time through minimally invasive liquid biopsies. To realize this potential, however, methods for molecular analysis of these rare cells must be developed and validated. Here, we describe the integration of imaging mass cytometry (IMC) using metal-labeled antibodies as implemented on the Fluidigm Hyperion Imaging System into the workflow of the previously established High Definition Single Cell Analysis (HD-SCA) assay for liquid biopsies, along with methods for image analysis and signal normalization. Using liquid biopsies from a metastatic prostate cancer case, we demonstrate that IMC can extend the reach of CTC characterization to include dozens of protein biomarkers, with the potential to understand a range of biological properties that could affect therapeutic response, metastasis and immune surveillance when coupled with simultaneous phenotyping of thousands of leukocytes.